Ro 25-6981 maleate
Potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit. IC50 values are 0.009 and 52 μM for cloned receptor subunit combinations NR1C/NR2B and NR1C/NR2A respectively. Displays neuroprotectant effects in vivo and in vitro.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||4.56||10mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 455.55. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.2 mL||10.98 mL||21.95 mL|
|5 mM||0.44 mL||2.2 mL||4.39 mL|
|10 mM||0.22 mL||1.1 mL||2.2 mL|
|50 mM||0.04 mL||0.22 mL||0.44 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Fischer et al (1997) Ro 25-6981, a highly potent and selective blocker of N-Methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J.Pharmacol.Exp.Ther. 283 1285 PMID: 9400004
Kosowski and Liljequist (2004) The NR2B- selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [(±)-(R*,S*)-α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamin J.Pharmacol.Exp.Ther. 311 560 PMID: 15256539
Lynch et al (2001) Pharmacological characterization of interactions of RO 25-6981 with the NR2B (ε2) subunit. Eur.J.Pharmacol. 416 185 PMID: 11290368
If you know of a relevant reference for Ro 25-6981 maleate, please let us know.
View Related Products by Product Action
Keywords: Subtype-selective NR2B antagonists Glutamate NMDA Receptors N-Methyl-D-Aspartate iGlur Ionotropic Ro25-6981 maleate NMDA Receptors
22 Citations for Ro 25-6981 maleate
Citations are publications that use Tocris products. Selected citations for Ro 25-6981 maleate include:
Nebieridze et al (2012) β-Estradiol unmasks metabotropic receptor-mediated metaplasticity of NMDA receptor transmission in the female rat dentate gyrus. PLoS One 37 1845 PMID: 22541715
Ishima and Hashimoto (2012) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of σ-1 and IP3 receptors. Neurobiol Learn Mem 7 e37989 PMID: 22655093
Noel et al (2011) Tissue plasminogen activator is required for the development of fetal alcohol syndrome in mice. Proc Natl Acad Sci U S A 108 5069 PMID: 21383198
Xie et al (2011) Dependence of NMDA/GSK-3β mediated metaplasticity on TRPM2 channels at hippocampal CA3-CA1 synapses. J Neurosci 4 44 PMID: 22188973
Terasaki et al (2010) Activation of NR2A receptors induces ischemic tolerance through CREB signaling. J Cereb Blood Flow Metab 30 1441 PMID: 20145658
Hellier et al (2009) NMDA receptor-mediated long-term alterations in epileptiform activity in experimental chronic epilepsy. Neuropharmacology 56 414 PMID: 18930747
Beazely et al (2009) Platelet-derived growth factor selectively inhibits NR2B-containing N-methyl-D-aspartate receptors in CA1 hippocampal neurons. J Biol Chem 284 8054 PMID: 19106110
Popp et al (2008) Cerebellar granule cells cultured from adolescent rats express functional NMDA receptors: an in vitro model for studying the developing cerebellum. J Neurochem 106 900 PMID: 18466339
Ge et al (2007) A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron 54 559 PMID: 17521569
France (2017) Multiple roles of GluN2B-containing NMDA receptors in synaptic plasticity in juvenile hippocampus. Neuropharmacology 112 76 PMID: 27523302
Volkmann et al (2016) MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit. PLoS One 11 e0148129 PMID: 26829109
Chen et al (2016) β-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain. Nature Communications 7 12531 PMID: 27538456
Lauderdale et al (2015) Osmotic Edema Rapidly Increases Neuronal Excitability Through Activation of NMDA Receptor-Dependent Slow Inward Currents in Juvenile and Adult Hippocampus. ASN Neuro 7 PMID: 26489684
Tindi et al (2015) ANKS1B Gene Product AIDA-1 Controls Hippocampal Synaptic Transmission by Regulating GluN2B Subunit Localization. J Neurosci 35 8986 PMID: 26085624
Smith et al (2014) A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation. Mol Pharmacol 86 390 PMID: 25057049
Trepanier et al (2013) Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase. Sci Rep 3 926 PMID: 23378895
Hamida et al (2013) Protein tyrosine phosphatase α in the dorsomedial striatum promotes excessive ethanol-drinking behaviors. Transl Psychiatry 33 14369 PMID: 24005290
Louderback et al (2013) Knockdown of BNST GluN2B-containing NMDA receptors mimics the actions of ketamine on novelty-induced hypophagia. Psychoneuroendocrinology 3 e331 PMID: 24301649
Urban et al (2013) Treatment with a clinically-relevant dose of methylphenidate alters NMDA receptor composition and synaptic plasticity in the juvenile rat prefrontal cortex. Mol Brain 101 65 PMID: 23333502
Hoshiko et al (2012) Deficiency of the microglial receptor CX3CR1 impairs postnatal functional development of thalamocortical synapses in the barrel cortex. J Neurosci 32 15106 PMID: 23100431
Olsen and Sheng (2012) NMDA receptors and BAX are essential for Aβ impairment of LTP. Sci Rep 2 225 PMID: 22355739
Bortolato et al (2012) NMDARs mediate the role of monoamine oxidase A in pathological aggression. J Neurosci 32 8574 PMID: 22723698
Do you know of a great paper that uses Ro 25-6981 maleate from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.